Drug intelligence / Profile preview

abidol

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Abidol is an antiviral drug that has been investigated for the treatment of coronavirus disease 2019 (COVID-19). It has been studied in various clinical settings, including prospective/retrospective randomized controlled clinical studies and retrospective cohort studies, to evaluate its efficacy and safety in patients with COVID-19. While some studies suggest a potential role in reducing in-hospital mortality and shortening viral shedding duration, others indicate no superior efficacy compared to other antiviral drugs. Gastrointestinal side effects and an increase in bilirubin have been noted as potential adverse reactions.

Brand names: Arbidol
Other names: abidol hydrochloride

Targets

HMPV F (Human metapneumovirus fusion protein)Mpro (3C-like proteinase of SARS-CoV-2)HA stem (Influenza A hemagglutinin stem region)

Beyond the preview

Go deeper on abidol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abidol.

Explore the full profile